These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

715 related items for PubMed ID: 22763386

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.
    Morabito F, Gentile M, Mazzone C, Rossi D, Di Raimondo F, Bringhen S, Ria R, Offidani M, Patriarca F, Nozzoli C, Petrucci MT, Benevolo G, Vincelli I, Guglielmelli T, Grasso M, Marasca R, Baldini L, Montefusco V, Musto P, Cascavilla N, Majolino I, Musolino C, Cavo M, Boccadoro M, Palumbo A.
    Blood; 2011 Nov 24; 118(22):5759-66. PubMed ID: 21951682
    [Abstract] [Full Text] [Related]

  • 23. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
    San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG, VISTA Trial Investigators.
    N Engl J Med; 2008 Aug 28; 359(9):906-17. PubMed ID: 18753647
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients.
    Kleber M, Ihorst G, Deschler B, Jakob C, Liebisch P, Koch B, Sezer O, Engelhardt M.
    Eur J Haematol; 2009 Dec 01; 83(6):519-27. PubMed ID: 19614956
    [Abstract] [Full Text] [Related]

  • 29. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG.
    Cancer; 2007 Sep 01; 110(5):1042-9. PubMed ID: 17654660
    [Abstract] [Full Text] [Related]

  • 30. Bortezomib and dexamethasone in previously untreated multiple myeloma associated with renal failure and reversal of renal failure.
    Malani AK, Gupta V, Rangineni R.
    Acta Haematol; 2006 Sep 01; 116(4):255-8. PubMed ID: 17119326
    [Abstract] [Full Text] [Related]

  • 31. Advances in therapy of multiple myeloma.
    Bladé J, Rosiñol L.
    Curr Opin Oncol; 2008 Nov 01; 20(6):697-704. PubMed ID: 18841053
    [Abstract] [Full Text] [Related]

  • 32. Evolving chemotherapy options for the treatment of myeloma kidney: a 40-year perspective.
    Kastritis E, Dimopoulos MA, Bladé J.
    Adv Chronic Kidney Dis; 2012 Sep 01; 19(5):312-23. PubMed ID: 22920642
    [Abstract] [Full Text] [Related]

  • 33. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.
    Dimopoulos MA, Cheung MC, Roussel M, Liu T, Gamberi B, Kolb B, Derigs HG, Eom H, Belhadj K, Lenain P, Van der Jagt R, Rigaudeau S, Dib M, Hall R, Jardel H, Jaccard A, Tosikyan A, Karlin L, Bensinger W, Schots R, Leupin N, Chen G, Marek J, Ervin-Haynes A, Facon T.
    Haematologica; 2016 Mar 01; 101(3):363-70. PubMed ID: 26659916
    [Abstract] [Full Text] [Related]

  • 34. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment.
    Dimopoulos MA, Christoulas D, Roussou M, Kastritis E, Migkou M, Gavriatopoulou M, Matsouka C, Mparmparoussi D, Psimenou E, Grapsa I, Efstathiou E, Terpos E.
    Eur J Haematol; 2010 Jul 01; 85(1):1-5. PubMed ID: 20192988
    [Abstract] [Full Text] [Related]

  • 35. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
    Kaufman JL, Nooka A, Vrana M, Gleason C, Heffner LT, Lonial S.
    Cancer; 2010 Jul 01; 116(13):3143-51. PubMed ID: 20564642
    [Abstract] [Full Text] [Related]

  • 36. Bortezomib in the front-line treatment of multiple myeloma.
    Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Munshi N, Anderson KC.
    Expert Rev Anticancer Ther; 2008 Jul 01; 8(7):1053-72. PubMed ID: 18588451
    [Abstract] [Full Text] [Related]

  • 37. Treatment of multiple myeloma in the targeted therapy era.
    Saad AA, Sharma M, Higa GM.
    Ann Pharmacother; 2009 Feb 01; 43(2):329-38. PubMed ID: 19193585
    [Abstract] [Full Text] [Related]

  • 38. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
    Zheng W, Wei G, Ye X, He J, Li L, Wu W, Shi J, Zhang J, Huang W, Xie W, Luo Y, Xue X, Lin M, Huang H, Cai Z.
    Leuk Res; 2009 Dec 01; 33(12):1615-8. PubMed ID: 19773080
    [Abstract] [Full Text] [Related]

  • 39. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents.
    Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsouka C, Barmparousi D, Grapsa I, Psimenou E, Bamias A, Dimopoulos MA.
    Haematologica; 2007 Apr 01; 92(4):546-9. PubMed ID: 17488666
    [Abstract] [Full Text] [Related]

  • 40. Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates.
    Kristinsson SY, Landgren O, Rajkumar VS.
    Cancer J; 2009 Apr 01; 15(6):473-8. PubMed ID: 20010166
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 36.